CDKN2A and carcinoma: Likewise, patients with HPVDNA+/p16+ TSCC/BOTSCC presented a better OS and DFS compared to those with HPVDNA−/p16− tumors, while notably, those with HPVDNA−/p16+ carcinomas presented an intermediate survival.